breast-cancer
This review focuses on surface-functionalized polymeric nanoparticles for active targeting of breast cancer cells. Ligands like folic acid (folate receptor), hyaluronic acid (CD44), aptamers, and peptides (HER2) enable receptor-mediated endocytosis, improving drug delivery to cancer cells while…
breast-cancer
Systematic comparison of four breast cancer chemotherapy regimens in female mice found paclitaxel caused the most prolonged central pro-inflammatory signaling and cisplatin caused the most sustained gut microbiome disruption. Cyclophosphamide and doxorubicin had more modest effects on the gut-brain…
breast-cancer
Molecular dynamics simulations of HER2 D769H and D769Y mutations showed contrasting effects. D769H destabilized the drug complex (equilibrium at 100 ps vs. 150 ps for wild-type, suggesting reduced drug retention). D769Y enhanced ligand binding beyond wild-type strength. Both mutations increased…
breast-cancer
Analysis of 4,400+ breast cancer patients found women under 50 with grade 1 tumors ≤1 cm and no LVI had just 4.92% lymph node metastasis rate—nearly identical to the 5.95% in women ≥50 with the same features. Age alone does not determine nodal risk in low-risk breast cancer.
breast-cancer
Applying Christensen's disruptive innovation framework to breast cancer therapy: mutation-anchored agents underperform due to resistance escape routes, while broadly acting host-driven therapies (ADCs, immunotherapy, cell/gene therapies) succeed by acting through harder-to-escape mechanisms across…
breast-cancer
Ductal carcinoma in situ (DCIS) — sometimes called 'stage 0' breast cancer — is a pre-invasive condition where cancer cells are confined to milk ducts and haven't spread. For years, standard treatment was surgery (lumpectomy or mastectomy), but many researchers have questioned whether DCIS…
breast-cancer
Following breast cancer treatment, recurrence at the original tumor site (locoregional recurrence, LRR) is a significant concern. This Dutch registry study examined outcomes of a tailored radiotherapy approach where the extent of radiation to lymph nodes was guided by individual patient nodal…
breast-cancer
This report highlights the experience of women who undergo mastectomy for cancer prevention or treatment and subsequently develop chronic pain — a condition known as post-mastectomy pain syndrome (PMPS). Through patient stories and clinical context, the piece illuminates how common yet poorly…
breast-cancer
Radiation therapy to the breast — particularly left-sided breast cancer — can expose the heart to damaging doses of radiation, leading to increased cardiovascular disease risk years or decades later. This was a known serious late effect of older radiation techniques.
breast-cancer
Before a cancer fully forms, cells go through a preneoplastic phase — a kind of 'almost cancer' state. A new study reveals that tunneling nanotubes (TNTs), thin actin-rich tubes that cells use to communicate over long distances, play a surprising role in this early transformation of breast tissue.
breast-cancer
Metabolic enzyme SIRT5 drives chemotherapy resistance in triple-negative breast cancer by rewiring energy pathways Triple-negative breast cancer (TNBC) has the worst prognosis among breast cancer subtypes, partly because a significant fraction of patients don't respond to chemotherapy even at first treatment. This study used proteomics and metabolomics on
breast-cancer
RUNX1 loss combined with p53 deletion creates aggressive ER+ breast tumors with immune cell infiltration RUNX1 is a transcription factor that is mutated in a subset of estrogen receptor-positive (ER+) breast cancers, but whether RUNX1 loss actually causes tumors to form has been unclear. Using genetically engineered mice with mammary-specific